Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen.
Saved in:
| Title: | Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen. |
|---|---|
| Authors: | Giubilaro J; Department of Pharmacology and Therapeutics, McGill University, Montréal, QC, Canada.; Research Institute of the McGill University Health Center (RI-MUHC), Montreal, QC, Canada., Schuetz DA; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, Canada., Stepniewski TM; Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences of Pompeu, Fabra University (UPF)-Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; InterAx Biotech AG, Villigen, Switzerland., Namkung Y; Research Institute of the McGill University Health Center (RI-MUHC), Montreal, QC, Canada.; Department of Medicine, Research Institute of the McGill University Health Center (RI-MUHC), McGill University, Montréal, QC, Canada., Khoury E; Department of Medicine, Research Institute of the McGill University Health Center (RI-MUHC), McGill University, Montréal, QC, Canada., Lara-Márquez M; Research Institute of the McGill University Health Center (RI-MUHC), Montreal, QC, Canada.; Department of Anatomy and Cell Biology, McGill University, Montréal, QC, Canada., Campbell S; Department of Pharmacology and Physiology, Université de Montréal, Montréal, QC, Canada., Beautrait A; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, Canada.; Schrödinger, Inc., New York, NY, United States., Armando S; Department of Medicine, Research Institute of the McGill University Health Center (RI-MUHC), McGill University, Montréal, QC, Canada., Radresa O; Department of Medicine, Research Institute of the McGill University Health Center (RI-MUHC), McGill University, Montréal, QC, Canada., Duchaine J; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, Canada., Lamarche-Vane N; Research Institute of the McGill University Health Center (RI-MUHC), Montreal, QC, Canada.; Department of Anatomy and Cell Biology, McGill University, Montréal, QC, Canada., Claing A; Department of Pharmacology and Physiology, Université de Montréal, Montréal, QC, Canada., Selent J; Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences of Pompeu, Fabra University (UPF)-Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Bouvier M; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, Canada.; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, Canada., Marinier A; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, Canada., Laporte SA; Department of Pharmacology and Therapeutics, McGill University, Montréal, QC, Canada. stephane.laporte@mcgill.ca.; Research Institute of the McGill University Health Center (RI-MUHC), Montreal, QC, Canada. stephane.laporte@mcgill.ca.; Department of Medicine, Research Institute of the McGill University Health Center (RI-MUHC), McGill University, Montréal, QC, Canada. stephane.laporte@mcgill.ca. |
| Source: | Nature communications [Nat Commun] 2021 Aug 03; Vol. 12 (1), pp. 4688. Date of Electronic Publication: 2021 Aug 03. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
